Daiichi Sankyo Company, Limited, commonly referred to as Daiichi Sankyo, is a prominent global pharmaceutical firm headquartered in Tokyo, Japan. Founded in 1899, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative healthcare solutions. Specialising in the research, development, and manufacturing of pharmaceuticals, Daiichi Sankyo is particularly renowned for its contributions to oncology, cardiovascular, and vaccine development. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, positioning it as a leader in the pharmaceutical industry. With a rich history marked by key milestones, Daiichi Sankyo has achieved notable success, including the development of groundbreaking therapies that have transformed treatment paradigms. Its dedication to innovation and quality has solidified its reputation as a trusted name in healthcare worldwide.
How does Daiichi Sankyo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo's score of 36 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Daiichi Sankyo reported total carbon emissions of approximately 4,602,874,000 kg CO2e globally. This includes 82,658,000 kg CO2e from Scope 1 emissions and 24,063,000 kg CO2e from Scope 2 emissions, while Scope 3 emissions accounted for a significant 4,496,153,000 kg CO2e. In Japan, the company recorded Scope 1 emissions of about 63,004,000 kg CO2e and Scope 2 emissions of approximately 2,173,000 kg CO2e. Daiichi Sankyo has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions by fiscal year 2050 for both Scope 1 and Scope 2 emissions. This long-term target reflects the company's commitment to sustainability and aligns with global climate initiatives. The company is currently on track to meet its five-year goals, demonstrating a proactive approach to reducing its carbon footprint. In Brazil, the reported emissions for 2023 were about 208,200 kg CO2e for Scope 1 and 2 combined, indicating a focused effort on local sustainability practices. Overall, Daiichi Sankyo's comprehensive emissions data and reduction targets underscore its dedication to addressing climate change and promoting environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 217,257,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 304,293,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daiichi Sankyo is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.